Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Scope of the Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.1.1 Introduction
4.1.2 Increase in preference for minimally invasive procedures
4.1.3 Increasing prevalence of cardiovascular diseases
4.1.4 Favorable reimbursement policies
4.2 Restraints
4.2.1 Strict regulatory guidelines
4.2.2 Risk of infection
4.3 Opportunities
4.3.1 New advancements in novel cardiac catheterization devices
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D and Designing
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porter's Five Forces Model
5.2.1 Bargaining power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitutes
5.2.5 Intensity of Rivalry
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Transcatheter Market, By Type of Treatment
6.1 Overview
6.1.1 Transfemoral Approach
6.1.2 Transapical Approach
6.1.3 Transaortic Approach
7 Global Transcatheter Market, By Product Type
7.1 Introduction
7.1.1 Transcatheter Aortic Valve Replacement (TAVR)
7.1.2 Transcatheter Mitral Valve Repair (TMVR)
8 Global Transcatheter Market, By End User
8.1 Introduction
8.1.1 Hospitals
8.1.2 Ambulatory Surgical Centres (ASCs)
8.1.3 Cardiac Catheterization Laboratory
9 Global Transcatheter Market, By Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Germany
9.3.2 U.K
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
10 Company Landscape
10.1 Company Market Share Analysis
10.1.1 Introduction
10.2 Competitive Landscape
10.2.1 Introduction
10.3 Key Developments
11 Company Profiles
11.1 Edwards Lifesciences Corporation
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products Offering
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 1.1.6 Key Strategy
11.2 Meril Life Sciences Pvt. Ltd.
11.2.1 1.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products Offering
11.2.4 Key Developments
11.2.5 1.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 Braile Biomedica
11.3.1 1.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products Offering
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Venus Medtech
11.4.1 1.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products Offering
11.4.4 Key Developments
11.4.5 Key Strategy
11.5 Boston Scientific Corporation
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products Offering
11.5.4 Key Developments
11.5.5 Key Strategy
11.6 JenaValve Technology, Inc.
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offering
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 Abbott Laboratories
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products Offering
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 1.7.6 Key Strategy
11.8 Medtronic PLC
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products Offering
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Bracco Diagnostic Inc.
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products Offering
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
11.1 Cook Medical Inc.
11.10.1 Company Overview
11.10.2 Financial Overview:
11.10.3 Products Offering
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key strategy
12 Appendix
12.1 Discussion Blue Print
12.2 Reference